Cell Signaling Technology

Product Pathways - Lymphocyte Signaling

TAP2 Antibody #12259

Applications Reactivity Sensitivity MW (kDa) Source
W IP H (Mk) Endogenous 72 Rabbit

Applications Key:  W=Western Blotting  IP=Immunoprecipitation
Reactivity Key:  H=Human  Mk=Monkey
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

TAP2 Antibody recognizes endogenous levels of total TAP2 protein.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Phe588 of human TAP2 protein. Antibodies are purified by protein A and peptide affinity chromatography.

Western Blotting

Western Blotting

Western blot analysis of extracts from HeLa and HT-29 cells, untreated (-) or treated with Human Interferon-γ (hIFN-γ) #8901 (10 ng/ml, 16 hr; +), using TAP2 Antibody (upper) or β-Actin (D6A8) Rabbit mAb #8457 (lower).

IP

IP

Immunoprecipitation of TAP2 from HeLa cell extracts treated with Human Interferon-γ (hIFN-γ) #8901 (10 ng/ml, 16 hr), using Normal Rabbit IgG #2729 (lane 2) or TAP2 Antibody (lane 3). Lane 1 is 10% input. Western blot analysis was performed using TAP2 Antibody.

Background

CD8+ cytotoxic T cells recognize peptides presented by MHC class I molecules on the surface of infected cells and tumor cells. The transporters associated with antigen processing 1 and 2 (TAP1 and TAP2) form the TAP complex which resides on the ER membrane and transports peptides from the cytoplasm into the ER for loading onto MHC class I molecules (1-8). In addition, TAP localized to endosomal membranes is important for cross-presentation by dendritic cells (9,10). IFN-γ produced by T cells and NK cells in response to infection causes upregulation of TAP1 and TAP2, resulting in increased antigen presentation to T cells (11). Some viral proteins inhibit TAP function or downregulate TAP expression resulting in viral immune evasion (12,13). In addition, investigators have observed reduced TAP expression in a variety of tumor types, and it is thought to be one mechanism for tumor immune evasion (14).

  1. Trowsdale, J. et al. (1990) Nature 348, 741-4.
  2. Spies, T. et al. (1990) Nature 348, 744-7.
  3. Deverson, E.V. et al. (1990) Nature 348, 738-41.
  4. Monaco, J.J. et al. (1990) Science 250, 1723-6.
  5. Spies, T. and DeMars, R. (1991) Nature 351, 323-4.
  6. Kleijmeer, M.J. et al. (1992) Nature 357, 342-4.
  7. Kelly, A. et al. (1992) Nature 355, 641-4.
  8. Spies, T. et al. (1992) Nature 355, 644-6.
  9. Huang, A.Y. et al. (1996) Immunity 4, 349-55.
  10. Guermonprez, P. et al. (2003) Nature 425, 397-402.
  11. Bahram, S. et al. (1991) Proc Natl Acad Sci U S A 88, 10094-8.
  12. Früh, K. et al. (1995) Nature 375, 415-8.
  13. Bennett, E.M. et al. (1999) J Immunol 162, 5049-52.
  14. Steer, H.J. et al. (2010) Oncogene 29, 6301-13.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Products